Adalvo announces the successful launch of Azelastine/Fluticasone nasal spray across several key European markets, strengthening its position in the allergy and respiratory segment.
Based on the reference brand Dymista®, the product is indicated for the treatment of seasonal and perennial allergic rhinitis, combining an antihistamine (Azelastine) with a corticosteroid (Fluticasone) for dual-action symptom relief. The formulation targets both early- and late-phase allergic responses, offering rapid and sustained efficacy.
According to IQVIA, Dymista® recorded global sales of approximately $335 million in 2024, with a three-year CAGR of 14%, reflecting consistent demand across mature markets.
Adalvo’s version is manufactured to meet EU quality standards and is delivered through a robust supply chain, ensuring reliable access for healthcare systems and commercial partners.
This launch is part of Adalvo’s broader strategy to deliver differentiated, partner-ready treatments across therapeutic areas with high clinical value and market relevance.
To explore licensing or commercial partnership opportunities within Adalvo’s respiratory portfolio, contact the team today.